Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Turk, Aleksander; Kunej, Tanja

doi:10.3389/fcvm.2022.931917

Cited by 6 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A string diagram was created to network identified loci (genes and SNP) and their association with cancer types and cardiovascular diseases. The network identified JAK2, TTN, TET2, and ATM with 16, 12, 8, and 6 edges, respectively [91]. These preliminary genetic identifications could be further evaluated in immunotherapy patients and linked to cardiotoxicity-related adverse events.…”

Section: Genetics As Risk Factorsmentioning

confidence: 90%

The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

Green,

Chacon,

Godinich

et al. 2023

Cancers

View full text Add to dashboard Cite

Cancer remains a prominent global cause of mortality, second only to cardiovascular disease. The past decades have witnessed substantial advancements in anti-cancer therapies, resulting in improved outcomes. Among these advancements, immunotherapy has emerged as a promising breakthrough, leveraging the immune system to target and eliminate cancer cells. Despite the remarkable potential of immunotherapy, concerns have arisen regarding associations with adverse cardiovascular events. This review examines the complex interplay between immunotherapy and cardiovascular toxicity and provides an overview of immunotherapy mechanisms, clinical perspectives, and potential biomarkers for adverse events, while delving into the intricate immune responses and evasion mechanisms displayed by cancer cells. The focus extends to the role of immune checkpoint inhibitors in cancer therapy, including CTLA-4, PD-1, and PD-L1 targeting antibodies. This review underscores the multifaceted challenges of managing immunotherapy-related cardiovascular toxicity. Risk factors for immune-related adverse events and major adverse cardiac events are explored, encompassing pharmacological, treatment-related, autoimmune, cardiovascular, tumor-related, social, genetic, and immune-related factors. The review also advocates for enhanced medical education and risk assessment tools to identify high-risk patients for preventive measures. Baseline cardiovascular evaluations, potential prophylactic strategies, and monitoring of emerging toxicity symptoms are discussed, along with the potential of adjunct anti-inflammatory therapies.

show abstract

Section: Genetics As Risk Factorsmentioning

confidence: 90%

The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

Green,

Chacon,

Godinich

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…19 20 Shared genetic factors have also been associated with elevated risk of CVD and cancer, including mutations of the JAK2, TTN, TET2 and ATM genes with gene network analyses highlighting links with DNA damage response pathways including homologous recombination. 21 Mutations in genes including TET2 are also implicated in clonal haematopoiesis of indeterminate potential (CHIP). CHIP is strongly linked with ageing, increased risk of haematological malignancies and CVD.…”

Section: Inherent Risk Factorsmentioning

confidence: 99%

Cardiovascular health: an important component of cancer survivorship

Cleary,

Rosen,

Gilbert

et al. 2023

bmjonc

View full text Add to dashboard Cite

Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types. Cancer and CVD share common aetiological risk factors, for example, age, tobacco use and obesity, as well as a shared inflammatory pathogenesis. The CV risks of mediastinal radiotherapy and chemotherapy, first observed in the 1970s with anthracyclines, have long been appreciated. More recently, targeted anticancer therapeutics (human epidermal growth factor receptor-2 targeted therpies, vascular endothelial growth factor inhibitors, second/third-generation BCR-ABL inhibitors, multiple myeloma therapies and combination RAF and MEK inhibitors in particular) as well as immunotherapies have added to the burden of treatment-related CV toxicity. Additionally, cancer therapy may indirectly impact on CV health by decreasing physical activity, increasing weight gain and accelerating the ageing process. Improving overall health outcomes by considering cardiological prevention and management in cancer survivorship is an area of increasing interest. CV risk factor assessment and management are recommended post-cancer treatment in accordance with primary prevention guidelines. The European Society of Cardiology 2022 guidelines also recommend enhanced surveillance after cancer treatments with a moderate to high risk of CV consequences. The aim of this article is to provide an overview of the interconnections between cancer and CVD, review current survivorship recommendations, and highlight key areas of ongoing and future research.

show abstract

“…In recent years, numerous studies have focused on common gene mutations in both diseases. Based on gene network analysis in a study, the most linked diseases were JAK2 , TTN , and TET2 , with the most closely associated diseases being perinatal cardiomyopathy, breast cancer, clonal hematopoiesis of indeterminate potential (CHIP), and coronary artery disease (CAD) [ 10 ]. Common gene mutations can be roughly classified into three pathways: inflammation, metabolism, and cell proliferation, all of which are closely related (Fig.…”

Section: Gene Mutationsmentioning

confidence: 99%

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

et al. 2023

View full text Add to dashboard Cite

Purpose of Review The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. Recent Findings Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. Summary This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.

show abstract

Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases

Cited by 6 publications

References 59 publications

The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

Cardiovascular health: an important component of cancer survivorship

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Contact Info

Product

Resources

About